Regulations.gov document
Development of Monoclonal Antibody Products Targeting SARS–CoV–2 for Emergency Use…
Notice · FDA-2020-D-1136 · posted Dec 21, 2023
Key facts
| Document ID | FDA-2020-D-1136-0084 |
|---|---|
| Title | Development of Monoclonal Antibody Products Targeting SARS–CoV–2 for Emergency Use Authorization; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2020-D-1136 |
| Posted | Dec 21, 2023 |
| Federal Register citation | 88 FR 88401 |
| FR document number | 2023-28092 |
| Effective date | Dec 21, 2023 |
At a glance
- 1–9 Pages
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: